SEARCH

SEARCH BY CITATION

References

  • 1
    Zhou BBS & Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408, 433439.
  • 2
    Shiloh Y (2006) The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 31, 402410.
  • 3
    Gasser S, Orsulic S, Brown EJ & Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 11861190.
  • 4
    Smirnov DA, Morley M, Shin E, Spielman RS & Cheung VG (2009) Genetic analysis of radiation-induced changes in human gene expression. Nature 459, 587591.
  • 5
    Chen G, Gharib TG, Huang CC, Taylor JMG, Misek DE, Kardia SLR, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM et al. (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1, 304313.
  • 6
    Hastie C, Saxton M, Akpan A, Cramer R, Masters JR & Naaby-Hansen S (2005) Combined affinity labeling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells. Oncogene 24, 59055913.
  • 7
    Dowling P, Meleady P, Dowd A, Henry M, Glynn S & Clynes M (2007) Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim Biophys Acta 1774, 93101.
  • 8
    Aggelis V, Craven RA, Peng J, Harnden P, Cairns DA, Maher ER, Tonge R, Selby PJ & Banks RE (2009) Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel–Lindau transfectant cell line model. Proteomics 9, 21182130.
  • 9
    Akahori Y, Kurosawa G, Sumitomo M, Morita M, Muramatsu C, Eguchi K, Tanaka M, Suzuki K, Sugiura M, Iba Y et al. (2009) Isolation of antigen/antibody complexes through organic solvent (ICOS) method. Biochem Biophys Res Commun 378, 832835.
  • 10
    Kurosawa G, Akahori Y, Morita M, Sumitomo M, Sato N, Muramatsu C, Eguchi K, Mastsuda K, Takasaki A, Tanaka M et al. (2008) Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic. Proc Natl Acad Sci USA 105, 72877292.
  • 11
    Ito W & Kurosawa Y (1993) Development of an artificial antibody system with multiple valency using an Fv fragment fused to a fragment of protein A. J Biol Chem 268, 2066820675.
  • 12
    Kurosawa G, Sumitomo M, Akahori Y, Matsuda K, Muramatsu C, Takasaki A, Iba Y, Eguchi K, Tanaka M, Suzuki K et al. (2009) Methods for comprehensive identification of membrane proteins recognized by a large number of monoclonal antibodies. J Immunol Methods 351, 112.
  • 13
    Brakenhoff RH, Gerretsen M, Knippels EMC, van Dijk M, van Essen H, Weghuis DO, Sinke RJ, Snow GB & van Dongen GAMS (1995) The human E48 antigen, highly homologous to murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell–cell adhesion. J Cell Biol 129, 16771689.
  • 14
    Quak JJ, Balm AJM, van Dongen GAMS, Brakkee JGP, Scheper RJ, Snow GB & Meijer CJLM (1990) A 22-kd surface antigen detected by monoclonal antibody E48 is exclusively expressed in stratified squamous and transitional epithelia. Am J Pathol 136, 191197.
  • 15
    Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM & Abraham RT (1999) Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59, 43754382.
  • 16
    Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G et al. (1994) Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 54, 24192423.
  • 17
    Sengupta S & Harris CC (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Cell Biol 6, 4455.
  • 18
    Bartek J & Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421429.
  • 19
    Syljuasen RG, Serensen CS, Hansen LT, Fugger K, Lundin C, Johannson F, Helleday T, Sehested M, Lukas J & Bartek J (2005) Inhibition of human Chk1 increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 25, 35533562.
  • 20
    Rubinfeld B, Upadhyay A, Clark SL, Fong SE, Smith V, Koeppen H, Ross S & Polakis P (2006) Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol 24, 205209.
  • 21
    Song J, Shih IM, Salani R, Chan DW & Zhang Z (2007) Annexin XI is associated with cysplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 13, 68426849.
  • 22
    Song J, Shih IM, Chan DW & Zhang Z (2009) Suppression of annexin A11 in ovarian cancer: implication in chemoresistance. NeoPlasia 11, 605614.
  • 23
    Gumley TP, McKenzie IFC & Sandrin MS (1995) Tissue expression, structure and function of the murine Ly-6 family of molecules. Immunol Cell Biol 73, 277296.
  • 24
    Gumley TP, McKenzie IFC, Kozak CA & Sandrin MS (1992) Isolation and characterization of cDNA clones for the mouse thymocyte B cell antigen (ThB). J Immunol 149, 26152618.
  • 25
    Inlay MA, Bhattacharya D, Sahoo D, Serwold T, Seita J, Karsunky H, Plevritis SK, Dill DL & Weissman IL (2009) Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Gene Dev 23, 23762381.
  • 26
    Brakenhoff RH, van Dijk M, Rood-Knippels EMC & Snow GB (1997) A gain of novel tissue specificity in the human Ly-6 gene E48. J Immunol 159, 48794886.
  • 27
    De Nooij-van Dalen AG, van Dongen GAMS, Smeets SJ, Nieuwenhuis EJC, Stinger-van Walsum M, Snow GB & Brakenhoff RH (2003) Characterization of the human Ly-6 antigens, the newly annotated member Ly-6k included, as molecular markers for head-and-neck squamous cell carcinoma. Int J Cancer 103, 768774.
  • 28
    Stroncek DF, Caruccio L & Bettionotti M (2004) CD177: a member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera. J Transl Med 2, 19.
  • 29
    Furuhata T, Tokino T, Urano T & Nakamura Y (1996) Isolation of a novel GPI-anchored gene specifically regulated by p53; correlation between its expression and anti-cancer drug sensitivity. Oncogene 13, 19651970.
  • 30
    Kimura Y, Furuhata T, Shiratsuchi T, Nishimori H, Hirata K, Nakamura Y & Tokino T (1997) GML sensitizes cancer cells to Toxol by induction of apoptosis. Oncogene 15, 13691374.
  • 31
    Higashiyama M, Miyoshi Y, Kodama K, Yokouchi H, Takami K, Nishijima M, Nakayama T, Kobayashi H, Minamigawa K & Nakamura Y (2000) p53-regulated GML gene expression in non-small cell lung cancer: a promising relationship to cisplatin chemosensitivity. Eur J Cancer 36, 489495.
  • 32
    El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW & Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1, 4549.
  • 33
    Kimura Y, Furuhata T, Urano T, Hirata K, Nakamura Y & Tokino T (1997) Genomic structure and chromosomal localization of GML (GPI-anchored molecule-like protein), a gene induced by p53. Genomics 41, 477480.
  • 34
    Morino K, Katsumi H, Akahori Y, Iba Y, Shinohara M, Ukai Y, Kohara Y & Kurosawa Y (2001) Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression. J Immunol Methods 257, 175184.
  • 35
    Masuda T, Saito N, Tomita M & Ishihama Y (2009) Unbiased quantitation of Escherichia coli membrane proteome using phase transfer surfactants. Mol Cell Proteomics 8, 27702777.
  • 36
    Iwasaki M, Masuda T, Tomita M & Ishihama Y (2009) Chemical cleavage-assisted tryptic digestion for membrane proteome analysis. J Proteome Res 8, 31693175.
  • 37
    Nieuwenhuis EJC, Leemans CR, Kummer A, Denkers F, Snow GB & Brakenhoff RH (2003) Assessment and clinical significance of micrometastases in lymph nodes of head and neck cancer patients detected by E48 (Ly-6D) quantitative reverse transcription-polymerase chain reaction. Lab Invest 83, 12331240.